ETTX News and Press, Entasis Therapeutics Holdings Inc. From 07/01/21

Entasis Therapeutics Holdings (ETTX) presents preclinical data on ETX0462, a novel diazabicyclooctane with antimicrobial activity against multidrug-resistant ((MDR)) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. Entasis scientists further demonstrated that the activi...

WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a no...

Entasis Therapeutics (ETTX) announces that it will present 11 posters with one oral presentation highlighting the company's ETX0462 treatment, a novel, diazabicyclooctane with antimicrobial activity against Pseudomonas aeruginosa.Shares up nearly 6% premarket.Presentations...

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 202...

These Insiders Decided To Buy Penny Stocks This Month Penny stocks , blue-chips, small-caps, whatever your focus, sentiment is starting to play a leading role. It’s not just about the next round of Reddit stocks to watch. What began on the social media forum site has exploded...

Enochian Biosciences (ENOB) +143% on FDA acceptance of pre-IND request for potential HIV cure.MediaCo Holding (MDIA) +63%.iTeos Therapeutics (ITOS) +52%.Entasis Therapeutics Holdings (ETTX) +25%.Orphazyme A/S (ORPH) +23%.Luokung Technology (LKCO) +22%.Mereo BioPharma Group plc (MREO) +17...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back from the weekend! We’re starting off another busy week of trading right with a look at the biggest pre-market stock movers for Monday. Source: f11photo/Shutterstock.com But before that. Consider...

Entasis Therapeutics (ETTX): Q1 GAAP EPS of -$0.29 beats by $0.07.Cash and cash equivalents of $44.9MPress Release For further details see: Entasis Therapeutics EPS beats by $0.07

– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage ...

Clinical-stage biopharmaceutical company Entasis Therapeutics Holdings (ETTX) has completed the initial closing of an ~$7.5M stock and warrant issuance to a subsidiary of Innoviva (INVA). Upon satisfaction of certain closing conditions, Innoviva will purchase the balance of the $20M...